Matching articles for "Haemophilus influenzae type b"

In Brief: A New Hib Booster

   
The Medical Letter on Drugs and Therapeutics • November 2, 2009;  (Issue 1324)
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in...
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old. Hiberix can also be given to children 12-15 months old as a scheduled booster dose.1

1. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008.

Download: U.S. English
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88 | Show Full IntroductionHide Full Introduction

Pediarix - a Combined Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003;  (Issue 1156)
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis...
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B), and a new inactivated polio component.
Med Lett Drugs Ther. 2003 May 12;45(1156):37-8 | Show Full IntroductionHide Full Introduction

H. Influenzae Vaccine For Infants

   
The Medical Letter on Drugs and Therapeutics • January 25, 1991;  (Issue 836)
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Med Lett Drugs Ther. 1991 Jan 25;33(836):5-7 | Show Full IntroductionHide Full Introduction

Conjugated Haemophilus Influenzae Type b Vaccine

   
The Medical Letter on Drugs and Therapeutics • April 22, 1988;  (Issue 764)
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid (ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older,...
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid (ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older, unconjugated H. influenzae vaccines (b- Capsa I; Hibimune; HibVAX) previously reviewed in The Medical Letter (Volume 27, page 61, 1985).
Med Lett Drugs Ther. 1988 Apr 22;30(764):47-8 | Show Full IntroductionHide Full Introduction